Amarin Corporation plc (AMRN)
AMRN Stock Price Chart
Explore Amarin Corporation plc interactive price chart. Choose custom timeframes to analyze AMRN price movements and trends.
AMRN Company Profile
Discover essential business fundamentals and corporate details for Amarin Corporation plc (AMRN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Apr 1993
Employees
275.00
Website
https://www.amarincorp.comCEO
Aaron D. Berg
Description
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
AMRN Financial Timeline
Browse a chronological timeline of Amarin Corporation plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Jul 2026
EPS estimate is -$0.01, while revenue estimate is $44.55m.
Earnings released on 29 Apr 2026
EPS came in at -$0.09 falling short of the estimated $0.01 by -1.00k%, while revenue for the quarter reached $45.13m , beating expectations by +3.11%.
Earnings released on 25 Feb 2026
EPS came in at $0.01 falling short of the estimated $0.07 by -85.71%, while revenue for the quarter reached $49.22m , missing expectations by -2.77%.
Earnings released on 29 Oct 2025
EPS came in at $0.01 falling short of the estimated $0.08 by -87.50%, while revenue for the quarter reached $49.67m , beating expectations by +15.25%.
Earnings released on 30 Jul 2025
EPS came in at -$0.03 surpassing the estimated -$0.66 by +95.45%, while revenue for the quarter reached $72.74m , beating expectations by +35.30%.
Earnings released on 7 May 2025
EPS came in at -$0.04 surpassing the estimated -$1.12 by +96.43%, while revenue for the quarter reached $41.04m , missing expectations by -19.14%.
Stock split effective on 11 Apr 2025
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Mar 2025
EPS came in at -$2.40 falling short of the estimated -$0.40 by -500.00%, while revenue for the quarter reached $62.31m , beating expectations by +73.30%.
Earnings released on 30 Oct 2024
EPS came in at -$1.00 falling short of the estimated -$1.00 by -0.05%, while revenue for the quarter reached $42.30m , missing expectations by -3.61%.
Earnings released on 31 Jul 2024
EPS came in at $0.20 surpassing the estimated -$0.04 by +600.00%, while revenue for the quarter reached $67.49m , beating expectations by +32.29%.
Earnings released on 1 May 2024
EPS came in at -$0.20 surpassing the estimated -$0.60 by +66.67%, while revenue for the quarter reached $55.16m , missing expectations by -3.31%.
Earnings released on 29 Feb 2024
EPS came in at -$0.01 surpassing the estimated -$0.03 by +66.67%, while revenue for the quarter reached $74.71m , beating expectations by +12.76%.
Earnings released on 1 Nov 2023
EPS came in at -$0.05 falling short of the estimated -$0.04 by -25.00%, while revenue for the quarter reached $66.06m , beating expectations by +12.63%.
Earnings released on 3 Aug 2023
EPS came in at -$0.04 matching the estimated -$0.04, while revenue for the quarter reached $80.17m , beating expectations by +7.58%.
Earnings released on 3 May 2023
EPS came in at -$0.04 falling short of the estimated -$0.03 by -33.33%, while revenue for the quarter reached $85.98m , beating expectations by +5.87%.
Earnings released on 1 Mar 2023
EPS came in at $0.40 surpassing the estimated -$0.01 by +4.90k%, while revenue for the quarter reached $90.25m , beating expectations by +3.44%.
Earnings released on 27 Oct 2022
EPS came in at -$0.01 surpassing the estimated -$0.40 by +97.50%, while revenue for the quarter reached $89.88m , beating expectations by +1.94%.
Earnings released on 3 Aug 2022
EPS came in at -$3.60 falling short of the estimated -$0.06 by -5.56k%, while revenue for the quarter reached $94.44m , beating expectations by +7.00%.
Earnings released on 4 May 2022
EPS came in at -$1.20 falling short of the estimated -$0.30 by -300.00%, while revenue for the quarter reached $94.63m , missing expectations by -26.24%.
Earnings released on 1 Mar 2022
EPS came in at $0.80 surpassing the estimated -$0.02 by +4.10k%, while revenue for the quarter reached $144.49m , beating expectations by +2.23%.
Earnings released on 3 Nov 2021
EPS came in at $0.60 surpassing the estimated -$0.20 by +400.00%, while revenue for the quarter reached $142.04m , missing expectations by -12.73%.
Earnings released on 5 Aug 2021
EPS came in at $0.60 surpassing the estimated -$1.00 by +160.00%, while revenue for the quarter reached $154.49m , beating expectations by +1.18%.
AMRN Stock Performance
Access detailed AMRN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
